{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000031","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.907766+00:00","generated_at":"2026-06-07T04:48:59.390078+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Xilio Therapeutics grants 177,000 RSUs to CEO and 20,000 RSUs to SVP in annual equity awards","bullets":["CEO René Russo granted 177,000 restricted stock units effective Jan 1, 2024.","SVP Kevin Brennan granted 20,000 restricted stock units effective same date.","RSUs vest in four equal annual installments beginning Jan 1, 2025, subject to continued service.","Awards granted under 2021 Stock Incentive Plan; form agreement filed as Exhibit 10.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000031","json":"https://secwatch.observer/filing/0001558370-24-000031.json","markdown":"https://secwatch.observer/filing/0001558370-24-000031.md","text":"https://secwatch.observer/filing/0001558370-24-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024000031/0001558370-24-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024000031/xlo-20240101x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:48:59.390078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}